Here are 5 fast facts about Celebrex and its generic sisters...

(Photo: Senate Special Committee on Aging)

1. Celebrex Manufacturer: Pfizer

(Photo: Robert Caplin/Bloomberg)

2. Generic Makers: 15 companies sell celecoxib in the United States

(Image: Aurobindo Pharma/FDA)

3. Celebrex, Average 2017 Spending per Dosage Unit: $10.27

4. Celecoxib, Average 2017 Spending per Dosage Unit: $1.61

Advertisement

5. Celebrex, 2017 U.S. Users: 13,384

Celecoxib, 2017 U.S. Users: 855,257

Data for this slideshow came from the Medicare Part D Drug Spending Dashboard.

U.S. prescription drug pricing is needlessly confusing, and that confusion may be hurting your clients’ health.

“Cost is the number one reason that patients are abandoning their prescriptions and not adhering to their medication treatments,” Pooja Babbrah, a health information technology consultant, testified earlier this month at a hearing on drug costs organized by the Senate Special Committee on Aging.

Confusion about drug coverage complicates sales of commercial health insurance and Medicare plans.

Retirees’ high out-of-pocket spending on prescriptions eats away at the income they get from any annuities or other income planning arrangements you have sold them.

(Related: Pass Catastrophic Medicare Plan Drug Costs to PBMs: Azar)

Sen. Susan Collins, R-Maine, the chairman of the Special Committee on Aging, said at the hearing that Americans are tapping their retirement funds, refinancing homes, and working multiple jobs to cover medication expense.

“In 2017, brand name prescription drug prices increased four times faster than the rate of inflation,” Collins said.

Both Republicans and Democrats in Washington have shown a strong interest in controlling drug prices. Policy differences remain, but there may be some hope for Congress passing drug price legislation.

Here are five ideas about drug prices that came up at the Senate hearing.

1. One culprit is the U.S. patent system.

Collins said drug prices are inflated, in part, by an opaque patent system.

“Humira – the world’s best-selling drug – is protected by more than 130 patents, some of which have terms that extend to 2034,” she said. “These patents block generic competition that could bring down the price for biologics.”

Collins has introduced S. 659, the “Biologic Patent Transparency Act” bill. The bill would discourage drug companies from introducing patents to keep competitors from introducing lower-priced alternatives.

2. Plan drug coverage rules are confusing.

Lisa Gill, the deputy editor of special projects at Consumer Reports, said Consumer Reports found that consumers with Medicare Part D prescription drug plans can have a hard time determining how well the drugs they need will be covered.

Consumers who pick plans based simply on the deductible amounts may overlook other coverage that could lower overall annual costs, Gill said.

3. Drug prices vary in strange ways.

The price of a drug can vary widely from pharmacy to pharmacy in a given region, and that can cost a consumer hundreds of dollars per year, Gill said.

In about 18% of the cases Consumer Reports reviewed, it would be cheaper for patients to pay cash and buy the drugs outside of the plan, Gill added.

Gill gave celecoxib — the generic version of Celebrex, a well-known nonsteroidal anti-inflammatory drug — as an example of that problem.

Buying generic Celebrex through a Cigna plan in Des Moines, Iowa, which does not include celecoxib on its formulary, would cost a consumer $212 a month, she said.

At Kroger, she said, the same drug is available for $6.

4. Health insurers usually use the full list prices of drugs to calculate the patients’ share of the costs.

Dr. Stacie Dusetzina, an associate professor of health policy at Vanderbilt University Medical Center, gave the new, high-cost hepatitis C drugs as example of how calculations of patients’ share of the costs now work.

A typical course of hepatitis C treatment takes 84 days. The list price for that course of treatment is $93,000.

Typical insurers and pharmacy benefits managers might pay $35,000.

A Medicare Part D plan would use the $93,000 list price to calculate the patient’s out-of-pocket costs, not the $35,000 discounted price, Dusetzina said.

In the Medicare program, “patients who need expensive drugs, or who need a lot of drugs, are subject to unlimited out-of-pocket spending,” Dusetzina said. “Insurance should be designed in a way that protects people from financial catastrophe when they’re sick, and today’s Medicare Part D program does not do that.”

5. Thoughts about airline ticket booking systems are still in the air.

Sen. Martha McSally, R-Ariz., said it’s not acceptable that people need to choose between food and medicine to pay for medicine, or that some people have to travel to Mexico to gets drugs they can afford.

Providing consumers with better pricing information should help bring prices down, she said.

“Why,” she asked, “can’t we have an Expedia.com of prescription drugs?”

A Senate Drug Price Bill Sampler

Here’s a look at three drug price bills senators mentioned at the Senate drug price hearing:

  • S. 469 – the “Affordable and Safe Prescription Drug Importation Act” bill (Sen. Bob Casey, D-Pa.): Would let Americans import medicine from Canada.
  • S. 2582 – the “Consumer Health Insurance Protection Act” bill (Sen. Elizabeth Warren, D-Mass.): Would ban insurers from dropping drug coverage mid-year and cap out-of-pocket drug costs at $250 a month for individuals and $500 for families.
  • S. 3754 – the “CURE High Drug Prices Act” bill (Sen. Richard Blumenthal, D-Conn.): Would require a drug’s maker to justify a big increase in the drug’s price.

Resources

Links to hearing resources, including a video recording and written versions of the witnesses’ testimony, are available here.

— Read Drugs Might Be the 2019 Health Cost Good Guy: CMS Actuarieson ThinkAdvisor.

— Connect with ThinkAdvisor Life/Health on LinkedIn and Twitter.